查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1679310

2030 年近视治疗市场预测：按类型、治疗方法、给药途径、年龄层、最终用户和地区进行的全球分析

Myopia Treatment Market Forecasts to 2030 - Global Analysis By Type (Simple Myopia,High Myopia, Pathological Myopia and Other Types), Treatment, Route of Administration, Age Group, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球近视治疗市场预计在 2024 年达到 12,5231 亿美元，到 2030 年将达到 22,6615.8 亿美元，预测期内的复合年增长率为 10.39%。近视治疗是指采用各种方法减缓、停止或矫正近视的发展。治疗方案包括处方眼镜或隐形眼镜、角膜塑型镜（角膜重塑镜片）、阿托品眼药水，以及LASIK或 PRK 等屈光矫正手术。近视管理策略，特别是针对儿童，旨在透过改变生活方式（例如增加户外活动和减少萤幕时间）来减缓近视的发展。近视管理的进步集中在创新的镜片和药物方法，以预防高度近视相关的併发症，如视网膜剥离和青光眼。

提高认识和诊断

透过扩大职场和学校的筛检倡议，可以早期发现病例。诊断技术的改进使得能够准确识别和快速做出反应。人们对阿托品眼药水、角膜塑形镜和矫正眼镜等可用治疗方法的了解不断增加，正在推动市场扩张。对数位眼睛疲劳的担忧和公共卫生措施促使眼部护理成为首要任务。由于对有效解决方案的需求不断增加，近视治疗市场正在迅速成长。

专科治疗方法有限

许多尖端治疗方法，例如阿托品眼药水和角膜塑形术，并不常见，尤其是在农村地区。由于获得有效治疗方法的机会有限，患者开始依赖传统的眼镜或隐形眼镜。高昂的价格和缺乏经验进一步阻碍了人们广泛获得专科治疗方法。此外，新兴国家缺乏基础设施和知识，阻碍了市场的发展。因此，儘管近视发病率不断上升，但市场拓展潜力仍有限。

远端医疗位眼保健解决方案

远距会诊有利于早期发现、快速矫正，进而降低高度近视的风险。在开立角膜塑形术和阿托品眼药水等矫正疗法时，人工智慧诊断工具可以提高准确性和效率。数位视觉治疗计划提供个人化的治疗方法，可提高患者的依从性和治疗效果。穿戴式科技和智慧型手机的广泛使用使得能够持续监测眼睛健康状况并鼓励主动管理。这些发展将提高近视治疗的有效性和便利性，进而促进市场发展。

治疗后併发症

LASIK和角膜塑形镜片的副作用，例如眼睛干涩、眩光、光晕和视力矫正退化，使人们不愿意接受这些手术。角膜感染疾病、视网膜脱落等严重的副作用使得患者和相关人员更加担心患者的安全。矫正手术和后续治疗的需求增加了费用并限制了近视治疗的机会。口碑和患者的负面经验可能会阻止潜在患者寻求治疗。结果，该行业面临成长潜力下降和采用率下降的问题。

COVID-19 的影响

COVID-19 疫情对近视治疗市场产生了重大影响，扰乱了供应链并推迟了选择性眼科护理程序。由于远距工作和线上学习而留在家中以及萤幕时间的增加，导致近视盛行率上升，尤其是在儿童中。虽然最初的限制措施导致患者咨询和治疗量下降，但随着人们对眼睛健康的意识提高，疫情后需求飙升。角膜塑形术、阿托品眼药水和创新矫正镜片的进步正在推动近视管理解决方案的市场復苏和长期成长。

预计预测期内单纯近视群体将占最大比重

由于全球范围内，尤其是在儿童和年轻人中，近视的盛行率不断上升，预计简单近视部分将在预测期内占据最大的市场占有率。萤幕使用时间的增加和户外活动的减少是导致病例增加的原因之一，从而刺激了对矫正解决方案的需求。专用隐形眼镜和角膜塑形术等光学治疗的进步进一步推动了市场的成长。此外，低剂量阿托品等药物介入的出现扩大了治疗选择。

预计预测期内，肠外药物部分将以最高的复合年增长率成长。

在预测期内，由于提供先进的药物传递方法，确保快速有效的治疗结果，预计肠外药物领域将实现最高的成长率。阿托品注射等注射疗法可以为高风险近视患者持续释放药物并减缓病情进展。该领域受益于生物製药和基因治疗技术的进步，提高了精准度和功效。新型注射药物研发投入的不断增加以及监管部门的核准进一步推动了市场的成长。高度近视盛行率的上升推动了对肠外干预的需求，从而影响了市场。

占比最大的地区：

在预测期内，由于近视患者数量的增加和对早期疗育意识的不断增强，预计北美将占据最大的市场占有率。角膜塑形术、阿托品眼药水和雷射手术等先进治疗方法越来越受欢迎。主要企业的存在、技术进步以及支持性医疗政策正在推动市场成长。隐形眼镜和手术技术的创新增加了儿童近视管理的需求。由于其强大的医疗保健基础设施和研究投入，美国占据市场主导地位，其次是加拿大。

复合年增长率最高的地区：

由于萤幕使用时间的增加和对眼睛健康的认识的不断提高，预计亚太地区在预测期内将呈现最高的复合年增长率。中国、日本和韩国等国家在先进的眼部保健解决方案和政府措施方面处于领先地位。角膜塑形镜、阿托品眼药水和外科手术的创新正在推动市场扩张。此外，可支配收入的增加和专门治疗的可用性也促进了需求。随着技术的不断进步，市场有望继续成长。

免费客製化服务：

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 主要企业的 SWOT 分析（最多 3 家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争性基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二手研究资料资讯来源
    • 先决条件

第三章 市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

第五章 全球近视治疗市场按类型

  • 单纯性近视
  • 严重近视
  • 病理性近视
  • 其他类型

第六章 全球近视治疗市场依治疗方法

  • 眼镜
  • 隐形眼镜
  • 屈光矫正手术
  • LASIK
  • 安慰剂
  • 角膜塑形术
  • 其他治疗方法

7. 全球近视治疗市场依给药途径划分

  • 口服
  • 肠外
  • 其他给药途径

第 8 章 全球近视治疗市场（依年龄层）

  • 儿童近视
  • 成人近视

第九章 全球近视治疗市场（依最终使用者）

  • 医院药房
  • 零售药局和眼镜店
  • 网路药局
  • 眼科门诊
  • 其他最终用户

第 10 章 全球近视治疗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Johnson & Johnson Vision
  • Novartis AG
  • CooperVision
  • Bausch & Lomb
  • EssilorLuxottica
  • Carl Zeiss Meditec AG
  • Alcon
  • Hoya Corporation
  • Nidek Co., Ltd.
  • STAAR Surgical Company
  • Ziemer Ophthalmic Systems AG
  • Menicon Co., Ltd.
  • SynergEyes, Inc.
  • Abbott Medical Optics Inc.
  • Visioneering Technologies, Inc.
  • Lumenis Ltd.
  • NeoVista, Inc.
  • Presbia PLC
Product Code: SMRC28893

According to Stratistics MRC, the Global Myopia Treatment Market is accounted for $12523.10 billion in 2024 and is expected to reach $22661.58 billion by 2030 growing at a CAGR of 10.39% during the forecast period. Myopia treatment refers to various methods used to slow, stop, or correct nearsightedness, a condition where distant objects appear blurry while close objects remain clear. Treatment options include prescription eyeglasses or contact lenses, orthokeratology (corneal reshaping lenses), atropine eye drops, and refractive surgeries like LASIK or PRK. Myopia management strategies, especially in children, aim to slow progression using lifestyle changes such as increased outdoor activities and reduced screen time. Advances in myopia control focus on innovative lenses and pharmaceutical approaches to prevent high myopia-related complications like retinal detachment and glaucoma.

Market Dynamics:

Driver:

Growing awareness and diagnosis

Early case detection is being achieved by expanded screening initiatives in workplaces and schools. Improvements in diagnostic technologies allow for accurate identification and prompt action. Growing knowledge of available treatments, such as atropine drops, orthokeratology, and corrective glasses, accelerates market expansion. Concerns about digital eye strain and public health initiatives further motivate people to give eye care first priority. As a consequence of the growing need for efficient solutions, the market for myopia treatments is growing quickly.

Restraint:

Limited availability of specialized treatments

Many cutting-edge therapies, such atropine eye drops and orthokeratology, are not generally available, particularly in rural regions. Patients become dependent on traditional eyeglasses and contact lenses as a result of this limitation in access to efficient remedies. The broad use of specialised therapies is further discouraged by high prices and a lack of experience. Additionally, market progress is slowed in emerging nations by a lack of infrastructure and knowledge. Consequently, even if the frequency of myopia is rising, the market's potential for expansion is still limited.

Opportunity:

Telemedicine and digital eye health solutions

Remote consultations lower the risk of developing severe myopia by facilitating early identification and prompt correction. When prescribing remedial therapies like orthokeratology and atropine drops, AI-powered diagnostic tools improve accuracy and efficiency. Programs for digital vision therapy offer individualised treatment regimens that enhance patient compliance and results. Proactive management is encouraged by the increased use of wearable technology and smartphones, which provide ongoing monitoring of eye health. These developments thereby increase market growth by improving the effectiveness and convenience of myopia therapy.

Threat:

Post-treatment complications

The side effects of LASIK or ortho-k lenses, including as dry eyes, glare, halos, and regression of vision correction, discourage people from pursuing these procedures. Serious side effects, such as corneal infections and retinal detachment, make patients and medical professionals even more concerned about patient safety. Costs are raised by the requirement for corrective surgery and follow-up therapies, which limits access to myopia therapy. Word-of-mouth and unfavourable patient experiences deter potential patients from seeking care. Consequently, the industry is confronted with reduced growth potential and slower adoption rates.

Covid-19 Impact

The COVID-19 pandemic significantly impacted the myopia treatment market, disrupting supply chains and delaying elective eye care procedures. Lockdowns and increased screen time due to remote work and online learning contributed to rising myopia cases, especially among children. While initial restrictions led to reduced patient visits and treatment adoption, demand surged post-pandemic as awareness of eye health grew. Advancements in orthokeratology, atropine eye drops, and innovative corrective lenses gained traction, driving market recovery and long-term growth in myopia management solutions.

The simple myopia segment is expected to be the largest during the forecast period

The simple myopia segment is expected to account for the largest market share during the forecast period, due to its rising global prevalence, especially among children and young adults. Increasing screen time and reduced outdoor activities contribute to the growing cases, fuelling demand for corrective solutions. Advancements in optical treatments, such as specialized contact lenses and orthokeratology, further boost market growth. Additionally, the availability of pharmacological interventions like low-dose atropine expands treatment options.

The parenteral segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the parenteral segment is predicted to witness the highest growth rate by offering advanced drug delivery methods that ensure rapid and effective therapeutic outcomes. Injectable treatments, such as atropine injections, provide sustained drug release, reducing progression in high-risk myopic patients. This segment benefits from technological advancements in biologics and gene therapy, enhancing precision and efficacy. Increased R&D investments and regulatory approvals for novel injectables further drive market growth. The rising prevalence of severe myopia cases boosts demand for parenteral interventions, reinforcing their market impact.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to rising cases of myopia and growing awareness of early intervention. Advanced treatments like orthokeratology, atropine eye drops, and laser surgery are gaining traction. The presence of key players, technological advancements, and supportive healthcare policies drive market growth. The demand for pediatric myopia management is increasing, with innovations in contact lenses and surgical options. The U.S. dominates the market, followed by Canada, due to strong healthcare infrastructure and research investments.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, owing to increasing screen time and growing awareness about eye health. Countries like China, Japan, and South Korea are at the forefront, driven by advanced eye care solutions and government initiatives. Innovations in orthokeratology lenses, atropine eye drops, and surgical procedures fuel market expansion. Additionally, rising disposable incomes and the availability of specialized treatments contribute to demand. The market is poised for continuous growth with ongoing technological advancements.

Key players in the market

Some of the key players profiled in the Myopia Treatment Market include Johnson & Johnson Vision, Novartis AG, CooperVision, Bausch & Lomb, EssilorLuxottica, Carl Zeiss Meditec AG, Alcon, Hoya Corporation, Nidek Co., Ltd., STAAR Surgical Company, Ziemer Ophthalmic Systems AG, Menicon Co., Ltd., SynergEyes, Inc., Abbott Medical Optics Inc., Visioneering Technologies, Inc., Lumenis Ltd., NeoVista, Inc. and Presbia PLC.

Key Developments:

In December 2024, EssilorLuxottica agreed to acquire Espansione Group, an Italy-based company specializing in non-invasive medical devices for diagnosing and treating dry-eye, ocular surface, and retinal diseases. This acquisition aims to strengthen EssilorLuxottica's position in the med-tech sector and enhance its portfolio of vision care solutions.

In July 2024, EssilorLuxottica announced the acquisition of a majority stake in Heidelberg Engineering, a German company specializing in ophthalmic diagnostic instruments. This acquisition is expected to bolster EssilorLuxottica's capabilities in providing comprehensive diagnostic and surgical solutions, supporting early diagnosis and treatment of eye conditions, including myopia.

In May 2023, EssilorLuxottica partnered with Chalhoub Group to form a joint venture focused on expanding retail eyewear presence in the Gulf Cooperation Council (GCC) region. The collaboration plans to open mono-brand and multi-brand stores for iconic global brands such as Ray-Ban, Persol, Oliver Peoples, and David Clulow, aiming to enhance customer service and experiences in the region.

Types Covered:

  • Simple Myopia
  • High Myopia
  • Pathological Myopia
  • Other Types

Treatments Covered:

  • Eyeglasses
  • Contact Lenses
  • Refractive Surgery
  • LASIK
  • PRK
  • Ortho-K
  • Other Treatments

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Other Route of Administrations

Age Groups Covered:

  • Pediatric Myopia
  • Adult Myopia

End Users Covered:

  • Hospital Pharmacies
  • Retail Pharmacies & Optical Stores
  • Online Pharmacies
  • Ophthalmology Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Myopia Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Simple Myopia
  • 5.3 High Myopia
  • 5.4 Pathological Myopia
  • 5.5 Other Types

6 Global Myopia Treatment Market, By Treatment

  • 6.1 Introduction
  • 6.2 Eyeglasses
  • 6.3 Contact Lenses
  • 6.4 Refractive Surgery
  • 6.5 LASIK
  • 6.6 PRK
  • 6.7 Ortho-K
  • 6.8 Other Treatments

7 Global Myopia Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral
  • 7.4 Other Route of Administrations

8 Global Myopia Treatment Market, By Age Group

  • 8.1 Introduction
  • 8.2 Pediatric Myopia
  • 8.3 Adult Myopia

9 Global Myopia Treatment Market, By End User

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies & Optical Stores
  • 9.4 Online Pharmacies
  • 9.5 Ophthalmology Clinics
  • 9.6 Other End Users

10 Global Myopia Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Johnson & Johnson Vision
  • 12.2 Novartis AG
  • 12.3 CooperVision
  • 12.4 Bausch & Lomb
  • 12.5 EssilorLuxottica
  • 12.6 Carl Zeiss Meditec AG
  • 12.7 Alcon
  • 12.8 Hoya Corporation
  • 12.9 Nidek Co., Ltd.
  • 12.10 STAAR Surgical Company
  • 12.11 Ziemer Ophthalmic Systems AG
  • 12.12 Menicon Co., Ltd.
  • 12.13 SynergEyes, Inc.
  • 12.14 Abbott Medical Optics Inc.
  • 12.15 Visioneering Technologies, Inc.
  • 12.16 Lumenis Ltd.
  • 12.17 NeoVista, Inc.
  • 12.18 Presbia PLC

List of Tables

  • Table 1 Global Myopia Treatment Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Myopia Treatment Market Outlook, By Type (2022-2030) ($MN)
  • Table 3 Global Myopia Treatment Market Outlook, By Simple Myopia (2022-2030) ($MN)
  • Table 4 Global Myopia Treatment Market Outlook, By High Myopia (2022-2030) ($MN)
  • Table 5 Global Myopia Treatment Market Outlook, By Pathological Myopia (2022-2030) ($MN)
  • Table 6 Global Myopia Treatment Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 7 Global Myopia Treatment Market Outlook, By Treatment (2022-2030) ($MN)
  • Table 8 Global Myopia Treatment Market Outlook, By Eyeglasses (2022-2030) ($MN)
  • Table 9 Global Myopia Treatment Market Outlook, By Contact Lenses (2022-2030) ($MN)
  • Table 10 Global Myopia Treatment Market Outlook, By Refractive Surgery (2022-2030) ($MN)
  • Table 11 Global Myopia Treatment Market Outlook, By LASIK (2022-2030) ($MN)
  • Table 12 Global Myopia Treatment Market Outlook, By PRK (2022-2030) ($MN)
  • Table 13 Global Myopia Treatment Market Outlook, By Ortho-K (2022-2030) ($MN)
  • Table 14 Global Myopia Treatment Market Outlook, By Other Treatments (2022-2030) ($MN)
  • Table 15 Global Myopia Treatment Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 16 Global Myopia Treatment Market Outlook, By Oral (2022-2030) ($MN)
  • Table 17 Global Myopia Treatment Market Outlook, By Parenteral (2022-2030) ($MN)
  • Table 18 Global Myopia Treatment Market Outlook, By Other Route of Administrations (2022-2030) ($MN)
  • Table 19 Global Myopia Treatment Market Outlook, By Age Group (2022-2030) ($MN)
  • Table 20 Global Myopia Treatment Market Outlook, By Pediatric Myopia (2022-2030) ($MN)
  • Table 21 Global Myopia Treatment Market Outlook, By Adult Myopia (2022-2030) ($MN)
  • Table 22 Global Myopia Treatment Market Outlook, By End User (2022-2030) ($MN)
  • Table 23 Global Myopia Treatment Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
  • Table 24 Global Myopia Treatment Market Outlook, By Retail Pharmacies & Optical Stores (2022-2030) ($MN)
  • Table 25 Global Myopia Treatment Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 26 Global Myopia Treatment Market Outlook, By Ophthalmology Clinics (2022-2030) ($MN)
  • Table 27 Global Myopia Treatment Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.